RUSC1

Summary

RUSC1 (RUN and SH3 domain containing 1, HGNC:17153) is a protein-coding gene on chromosome 1q22, encoding AP-4 complex accessory subunit RUSC1 (Q9BVN2). Associates with the adapter-like complex 4 (AP-4) and may therefore play a role in vesicular trafficking of proteins at the trans-Golgi network.

Predicted to enable actin binding activity. Involved in protein polyubiquitination. Located in cytosol.

Source: NCBI Gene 23623 — RefSeq curated summary.

At a glance

• GWAS associations: 16
• Clinical variants (ClinVar): 61 total
• MANE Select transcript: NM_001105203

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17153
Approved symbol	RUSC1
Name	RUN and SH3 domain containing 1
Location	1q22
Locus type	gene with protein product
Status	Approved
Aliases	NESCA
Ensembl gene	ENSG00000160753
Ensembl biotype	protein_coding
OMIM	617318
Entrez	23623

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 18 protein_coding, 4 retained_intron, 2 nonsense_mediated_decay

ENST00000292254, ENST00000368347, ENST00000368349, ENST00000368352, ENST00000368354, ENST00000462780, ENST00000467820, ENST00000468764, ENST00000471876, ENST00000473331, ENST00000479924, ENST00000485924, ENST00000489860, ENST00000490373, ENST00000492536, ENST00000497930, ENST00000696599, ENST00000878373, ENST00000878374, ENST00000878375, ENST00000878376, ENST00000878377, ENST00000925571, ENST00000955292

RefSeq mRNA: 8 — MANE Select: NM_001105203 NM_001105203, NM_001105204, NM_001105205, NM_001278227, NM_001278228, NM_001278229, NM_001278230, NM_014328

CCDS: CCDS1112, CCDS41410, CCDS41411, CCDS41412

Canonical transcript exons

ENST00000368352 — 10 exons

Exon	Start	End
ENSE00001910161	155326580	155327132
ENSE00003472217	155325864	155325910
ENSE00003563846	155324845	155324943
ENSE00003589081	155325316	155325490
ENSE00003621075	155325567	155325672
ENSE00003634623	155325102	155325178
ENSE00003967800	155321688	155323130
ENSE00003967804	155330403	155331114
ENSE00003967807	155328150	155328275
ENSE00003967810	155320894	155320991

Expression profiles

Bgee: expression breadth ubiquitous, 284 present calls, max score 97.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.3061 / max 1222.7925, expressed in 1810 samples.

FANTOM5 promoters (17 alternative TSS)

Promoter ID	TPM avg	Samples expressed
5617	19.1674	1760
5603	4.9686	863
5610	1.3385	936
5619	0.9410	523
5611	0.8778	412
5608	0.4515	255
5602	0.3320	114
5609	0.2927	95
5618	0.1787	73
5614	0.1680	32

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	97.25	gold quality
cortical plate	UBERON:0005343	96.98	gold quality
cerebellar hemisphere	UBERON:0002245	96.89	gold quality
cerebellar cortex	UBERON:0002129	96.82	gold quality
cerebellum	UBERON:0002037	96.18	gold quality
mucosa of transverse colon	UBERON:0004991	95.74	gold quality
right frontal lobe	UBERON:0002810	95.50	gold quality
ganglionic eminence	UBERON:0004023	94.64	gold quality
Brodmann (1909) area 10	UBERON:0013541	94.44	gold quality
lower esophagus mucosa	UBERON:0035834	94.36	gold quality
ileal mucosa	UBERON:0000331	94.18	gold quality
prefrontal cortex	UBERON:0000451	94.07	gold quality
frontal cortex	UBERON:0001870	93.82	gold quality
neocortex	UBERON:0001950	93.67	gold quality
paraflocculus	UBERON:0005351	93.60	gold quality
cervix squamous epithelium	UBERON:0006922	93.53	gold quality
right coronary artery	UBERON:0001625	93.42	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.41	gold quality
cingulate cortex	UBERON:0003027	93.33	gold quality
descending thoracic aorta	UBERON:0002345	93.31	gold quality
anterior cingulate cortex	UBERON:0009835	93.26	gold quality
thoracic aorta	UBERON:0001515	93.25	gold quality
ascending aorta	UBERON:0001496	93.24	gold quality
frontal pole	UBERON:0002795	93.13	gold quality
adenohypophysis	UBERON:0002196	93.09	gold quality
esophagus mucosa	UBERON:0002469	93.06	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.05	gold quality
transverse colon	UBERON:0001157	93.00	gold quality
middle temporal gyrus	UBERON:0002771	92.96	gold quality
hypothalamus	UBERON:0001898	92.88	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.07
E-GEOD-100618	no	646.13

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

63 targeting RUSC1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-3913-5P	99.78	67.26	968
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-2116-3P	99.74	64.32	889

Literature-anchored findings (GeneRIF, showing 6)

• Data show that NESCA and NEMO interact by their N-terminal region, that NESCA directly associates with TRAF6, which in turn catalyzes NESCA polyubiquitination, and that NESCA overexpression strongly inhibits TRAF6-mediated polyubiquitination of NEMO. (PMID:19365808)
• Nesca functions as an adapter involved in neuronal vesicular transport (PMID:22404429)
• RUN domain of NESCA can bind H-Ras, a downstream signaling molecule of TrkA, with high affinity. Moreover, NESCA RUN can directly interact with TrkA. (PMID:22821014)
• AP-4 deficiency causes missorting of ATG9A in diverse cell types, including patient-derived cells, as well as dysregulation of autophagy. (PMID:30262884)
• The present study demonstrated that lncRNA RUSC1ASN promoted cell viability and metastasis via Wnt/betacatenin signaling in human breast cancer. (PMID:30569097)
• LncRNA RUSC1-AS1 promotes osteosarcoma progression through regulating the miR-340-5p and PI3K/AKT pathway. (PMID:34048366)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rusc1	ENSDARG00000078125
mus_musculus	Rusc1	ENSMUSG00000041263
rattus_norvegicus	Fdps	ENSRNOG00000043377

Paralogs (1): RUSC2 (ENSG00000198853)

Protein

Protein identifiers

AP-4 complex accessory subunit RUSC1 — Q9BVN2 (reviewed: Q9BVN2)

Alternative names: New molecule containing SH3 at the carboxy-terminus, RUN and SH3 domain-containing protein 1

All UniProt accessions (9): Q9BVN2, A0A087WVK5, A0A087WW20, A0A087WX95, A0A087WYB2, A0A087WYU8, A0A087WZ68, A0A8Q3SIT1, Q68CX2

UniProt curated annotations — full annotation on UniProt →

Function. Associates with the adapter-like complex 4 (AP-4) and may therefore play a role in vesicular trafficking of proteins at the trans-Golgi network. Signaling adapter which plays a role in neuronal differentiation. Involved in regulation of NGF-dependent neurite outgrowth. May play a role in neuronal vesicular trafficking, specifically involving pre-synaptic membrane proteins. Seems to be involved in signaling pathways that are regulated by the prolonged activation of MAPK. Can regulate the polyubiquitination of IKBKG and thus may be involved in regulation of the NF-kappa-B pathway.

Subunit / interactions. Associated component of the adapter-like complex 4 (AP-4). Interacts with IKBKG and TRAF6. Interacts with F-actin, acetylated actin, TUBB3, STX1A, KIF5B and KLC1.

Subcellular location. Cytoplasm. Nucleus. Cytoskeleton. Cytoplasmic vesicle. Early endosome. Postsynaptic density. Golgi apparatus.

Tissue specificity. Predominantly expressed in brain.

Post-translational modifications. Phosphorylated on serine residues following nuclear translocation. Polyubiquitinated; polyubiquitination involves TRAF6.

Domain organisation. The RUN domain is necessary for NGF induced nuclear redistribution.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9BVN2-1	1	yes
Q9BVN2-2	2
Q9BVN2-3	3
Q9BVN2-4	4

RefSeq proteins (8): NP_001098673, NP_001098674, NP_001098675, NP_001265156, NP_001265157, NP_001265158, NP_001265159, NP_055143 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001452	SH3_domain	Domain
IPR004012	Run_dom	Domain
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR037213	Run_dom_sf	Homologous_superfamily
IPR047341	RUN_RUSC1	Domain
IPR047343	RUSC1_2	Family

Pfam: PF02759, PF14604

UniProt features (48 total): helix 12, region of interest 8, compositionally biased region 7, sequence conflict 7, splice variant 3, turn 3, domain 2, sequence variant 2, strand 2, chain 1, mutagenesis site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4GIW	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BVN2-F1	54.04	0.19

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
531	abrogates nuclear redistribution.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 158 (showing top): ATF_B, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, CREBP1_Q2, USF_C, PATIL_LIVER_CANCER, CREB_Q4, E4F1_Q6, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_POLYUBIQUITINATION, ATF3_Q6, chr1q22, GOMF_ACTIN_BINDING, BASAKI_YBX1_TARGETS_UP, DOUGLAS_BMI1_TARGETS_UP

GO Biological Process (1): protein polyubiquitination (GO:0000209)

GO Molecular Function (2): actin binding (GO:0003779), protein binding (GO:0005515)

GO Cellular Component (12): nucleus (GO:0005634), early endosome (GO:0005769), Golgi apparatus (GO:0005794), cytosol (GO:0005829), microtubule (GO:0005874), postsynaptic density (GO:0014069), microtubule cytoskeleton (GO:0015630), cytoplasmic vesicle (GO:0031410), cytoplasm (GO:0005737), endosome (GO:0005768), cytoskeleton (GO:0005856), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	3
intracellular membrane-bounded organelle	2
endomembrane system	2
cellular anatomical structure	2
protein ubiquitination	1
cytoskeletal protein binding	1
binding	1
endosome	1
microtubule cytoskeleton	1
polymeric cytoskeletal fiber	1
asymmetric synapse	1
postsynaptic specialization	1
cytoskeleton	1
intracellular vesicle	1
intracellular anatomical structure	1
cytoplasmic vesicle	1
intracellular membraneless organelle	1
cell junction	1

Protein interactions and networks

STRING

1714 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RUSC1	RUNDC3A	Q59EK9	793
RUSC1	SERINC1	Q9NRX5	594
RUSC1	AP4E1	Q9UPM8	521
RUSC1	ATG9A	Q7Z3C6	519
RUSC1	SERINC3	Q13530	516
RUSC1	RUFY1	Q96T51	473
RUSC1	CREBL2	O60519	456
RUSC1	AP4S1	Q9Y587	430
RUSC1	RUBCN	Q92622	426
RUSC1	ACBD4	Q8NC06	421
RUSC1	KREMEN2	Q8NCW0	419
RUSC1	RUFY3	Q7L099	419
RUSC1	TEPSIN	Q96N21	417
RUSC1	METRN	Q9UJH8	415
RUSC1	APBA2	Q99767	407

IntAct

305 interactions, top by confidence:

A	B	Type	Score
PNMA1	RUSC1	psi-mi:“MI:0915”(physical association)	0.790
RUSC1	PNMA1	psi-mi:“MI:0915”(physical association)	0.790
RUSC1	FAM9B	psi-mi:“MI:0915”(physical association)	0.670
RBPMS	RUSC1	psi-mi:“MI:0915”(physical association)	0.670
RUSC1	RBPMS	psi-mi:“MI:0915”(physical association)	0.670
FAM9B	RUSC1	psi-mi:“MI:0915”(physical association)	0.670
NUDT22	RUSC1	psi-mi:“MI:0915”(physical association)	0.600
WWP2	RUSC1	psi-mi:“MI:0915”(physical association)	0.560
STUB1	RUSC1	psi-mi:“MI:0915”(physical association)	0.560
RUSC1	STUB1	psi-mi:“MI:0915”(physical association)	0.560
RUSC1	ZNF620	psi-mi:“MI:0915”(physical association)	0.560
TBC1D25	RUSC1	psi-mi:“MI:0915”(physical association)	0.560
MAGEA3	RUSC1	psi-mi:“MI:0915”(physical association)	0.560
MAGEA6	RUSC1	psi-mi:“MI:0915”(physical association)	0.560
CTAG1A	RUSC1	psi-mi:“MI:0915”(physical association)	0.560
RBPMS	RUSC1	psi-mi:“MI:0915”(physical association)	0.560
EXOSC8	RUSC1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (108): RUSC1 (Two-hybrid), RUSC1 (Two-hybrid), RUSC1 (Two-hybrid), RUSC1 (Two-hybrid), FAM9B (Two-hybrid), RUSC1 (Two-hybrid), RUSC1 (Affinity Capture-MS), RUSC1 (Affinity Capture-MS), RUSC1 (Affinity Capture-MS), RUSC1 (Affinity Capture-MS), RUSC1 (Affinity Capture-MS), RUSC1 (Affinity Capture-RNA), RUSC1 (Affinity Capture-MS), RUSC1 (Two-hybrid), RUSC1 (Two-hybrid)

ESM2 similar proteins: A0A1B0GUS0, A0A5F9ZHS7, A7E346, A7MB34, A8MZG2, B2RU40, D4A9R4, O08574, O75593, P0C1Z6, P0CG20, Q0VG99, Q0ZCJ7, Q17QH7, Q29RM2, Q2KIS6, Q2M2S6, Q2M3G4, Q2NL68, Q32LE6, Q3U1J1, Q5JXC2, Q5R815, Q5SW24, Q61660, Q63247, Q6NZ36, Q6PBC9, Q6ZN01, Q6ZRI6, Q7TN08, Q7Z591, Q80VF6, Q86WR7, Q8BG26, Q8BP99, Q8BXQ8, Q8IYS4, Q8N9Y4, Q8NAV2

Diamond homologs: A4FU49, A5D7F8, A5D8S5, A6QLK6, A7E3N7, B1V8A0, D3ZG83, E2RP94, E7F1U2, F1LRS8, G5EC32, M0R4F8, O35413, O35964, O42287, O42854, O43586, O60504, O70145, O89100, O94875, P0CR78, P0CR79, P10569, P19878, P34258, P38753, P62484, P97306, Q07840, Q09822, Q10199, Q13588, Q15811, Q28E95, Q2KJA1, Q3B7M5, Q3UTJ2, Q4R729, Q5HYK7

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
TRAF6	“down-regulates quantity by destabilization”	RUSC1	polyubiquitination
RUSC1	“up-regulates quantity by stabilization”	IKBKG
RUSC1	up-regulates	Neurite_outgrowth	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1052 predictions. Top by Δscore:

Variant	Effect	Δscore
1:155325389:A:AG	acceptor_gain	1.0000
1:155325389:AC:A	acceptor_gain	1.0000
1:155325390:C:CA	acceptor_gain	1.0000
1:155325395:T:TA	acceptor_gain	1.0000
1:155325486:GCCAG:G	donor_gain	1.0000
1:155325487:CCAGG:C	donor_loss	1.0000
1:155325488:CAGGT:C	donor_loss	1.0000
1:155325489:AGGT:A	donor_loss	1.0000
1:155325491:GT:G	donor_loss	1.0000
1:155325901:G:GT	donor_gain	1.0000
1:155328144:TTTTA:T	acceptor_loss	1.0000
1:155328145:TTTA:T	acceptor_loss	1.0000
1:155328147:TA:T	acceptor_loss	1.0000
1:155328147:TAGGA:T	acceptor_gain	1.0000
1:155328148:A:AC	acceptor_loss	1.0000
1:155328148:A:AG	acceptor_gain	1.0000
1:155328148:AG:A	acceptor_gain	1.0000
1:155328148:AGGAG:A	acceptor_gain	1.0000
1:155328149:G:GA	acceptor_loss	1.0000
1:155328149:G:GG	acceptor_gain	1.0000
1:155328149:GG:G	acceptor_gain	1.0000
1:155328149:GGA:G	acceptor_gain	1.0000
1:155328273:TAGGT:T	donor_loss	1.0000
1:155328274:AGG:A	donor_loss	1.0000
1:155328275:GGT:G	donor_loss	1.0000
1:155328276:GTA:G	donor_loss	1.0000
1:155328277:T:A	donor_loss	1.0000
1:155325097:CCCA:C	acceptor_loss	0.9900
1:155325099:CA:C	acceptor_loss	0.9900
1:155325100:A:AG	acceptor_gain	0.9900

AlphaMissense

5781 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:155325129:T:A	V495D	0.998
1:155325149:T:C	F502L	0.998
1:155325151:C:A	F502L	0.998
1:155325151:C:G	F502L	0.998
1:155325150:T:C	F502S	0.997
1:155325178:G:C	K511N	0.997
1:155325178:G:T	K511N	0.997
1:155325376:T:C	C532R	0.997
1:155325666:T:C	L603P	0.997
1:155330456:T:C	F865S	0.997
1:155325359:T:C	L526P	0.996
1:155325386:T:C	L535P	0.996
1:155325669:T:C	L604P	0.996
1:155325883:T:A	W612R	0.995
1:155325883:T:C	W612R	0.995
1:155326688:T:C	L657P	0.995
1:155326693:T:C	F659L	0.995
1:155326695:C:A	F659L	0.995
1:155326695:C:G	F659L	0.995
1:155321808:T:C	L12P	0.994
1:155325117:T:A	V491D	0.994
1:155325138:T:G	I498S	0.994
1:155325374:T:C	L531P	0.994
1:155325386:T:A	L535H	0.994
1:155325669:T:A	L604H	0.994
1:155326670:T:C	L651P	0.994
1:155326694:T:C	F659S	0.994
1:155326700:T:C	L661P	0.994
1:155330455:T:C	F865L	0.994
1:155330457:C:A	F865L	0.994

dbSNP variants (sampled 300 via entrez): RS1000097114 (1:155328571 A>T), RS1000146031 (1:155328755 C>A,T), RS1001299987 (1:155328994 A>C), RS1001401431 (1:155329037 T>C), RS1001674000 (1:155328809 G>A,T), RS1002277075 (1:155328033 C>A), RS1003629295 (1:155330447 A>G), RS1003785765 (1:155323970 G>A), RS1003836399 (1:155324261 G>C), RS1004543884 (1:155331335 G>A), RS1004822135 (1:155324474 C>A,T), RS1005415302 (1:155323723 G>C), RS1005426257 (1:155323297 T>A,G), RS1005614574 (1:155327456 A>G), RS1005700122 (1:155323559 C>A,T)

Disease associations

OMIM: gene MIM:617318 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST004131_70	Inflammatory bowel disease	6.000000e-08
GCST004132_44	Crohn’s disease	2.000000e-07
GCST007294_124	Body fat distribution (trunk fat ratio)	8.000000e-35
GCST007294_3	Body fat distribution (trunk fat ratio)	6.000000e-21
GCST007294_50	Body fat distribution (trunk fat ratio)	1.000000e-15
GCST007295_17	Body fat distribution (leg fat ratio)	3.000000e-13
GCST007295_37	Body fat distribution (leg fat ratio)	7.000000e-17
GCST007295_72	Body fat distribution (leg fat ratio)	1.000000e-28
GCST010696_19	Cortical thickness (min-P)	2.000000e-10
GCST010697_10	Cortical surface area (min-P)	3.000000e-10
GCST010698_59	Subcortical volume (min-P)	9.000000e-10
GCST010699_20	Brain morphology (min-P)	7.000000e-10
GCST010700_5	Cortical thickness (MOSTest)	8.000000e-17
GCST010701_66	Cortical surface area (MOSTest)	1.000000e-09
GCST010702_43	Subcortical volume (MOSTest)	3.000000e-10
GCST010703_253	Brain morphology (MOSTest)	4.000000e-14

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004341	body fat distribution
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs11264359	FDPS, RUSC1	3	3.75	1	atorvastatin;Bisphosphonates

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, decreases expression	2
Cyclosporine	decreases expression	2
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
beta-lapachone	decreases expression	1
sodium arsenite	decreases expression	1
methacrylaldehyde	increases oxidation, increases abundance, affects cotreatment	1
CGP 52608	affects binding, increases reaction	1
ICG 001	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	increases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Plant Extracts	affects cotreatment, decreases expression	1
Smoke	decreases expression	1
Dronabinol	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	affects expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Antirheumatic Agents	increases expression	1
Okadaic Acid	increases expression	1
Particulate Matter	decreases expression, increases abundance	1
Volatile Organic Compounds	affects cotreatment, increases oxidation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.